Litcius/Paper detail

RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome

Makoto Nishio, Luis Paz‐Ares, Martin Reck, Kazuhiko Nakagawa, Edward B. Garon, Sanjay Popat, Matteo Ceccarelli, Hillary Graham, Carla Visseren‐Grul, Silvia Novello

2023Clinical Lung Cancer26 citationsDOI

Topics & Concepts

MedicineErlotinibInternal medicineLung cancerOncologyAfatinibRamucirumabProgression-free survivalCancerEpidermal growth factor receptorOverall survivalLung Cancer Treatments and MutationsCancer Immunotherapy and BiomarkersLung Cancer Research Studies
RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome | Litcius